FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Yanowitz Joel 2. Date of Event Requiring Statement (MM/DD/YYYY)
5/28/2021 

3. Issuer Name and Ticker or Trading Symbol Immune Therapeutics, Inc. [IMUN]
(Last)       (First)       (Middle)
100 TAMAL PLZ. SUITE 106
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
_____ Officer (give title below)        ___X___ Other (specify below)
/ Member of 10% owner group
(Street)
CORTE MADERA, CA 94925      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  4570 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants (Right to Buy)  1/9/2018  1/8/2024  Common Stock  20000  $5.00  D   

Explanation of Responses:
(1)  According to the Annual Report on Form 10-K filed on April 15, 2021 (the "Form 10-K") by the issuer, Immune Therapeutics, Inc. (the "Company"), a reverse stock split of the Company's issued and outstanding, but not authorized, common stock at a ratio of 1,000-to-1 (the "Reverse Split") was approved by the Company's shareholders. The Reverse Split is currently pending approval by the Financial Industry Regulatory Authority, Inc. The information contained in the Form 10-K relating to the shares of Common Stock outstanding and beneficially owned is based on the implementation of the Reverse Split. The information presented herein is likewise based on the implementation of the Reverse Split. The beneficial ownership information presented in this Form 3 is otherwise based on the beneficial ownership of the Reporting Persons as of the date of the event requiring filing of this Form 3.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Yanowitz Joel
100 TAMAL PLZ. SUITE 106
CORTE MADERA, CA 94925



Member of 10% owner group

Signatures
/s/ Joel Yanowitz 5/28/2021
**Signature of Reporting Person Date
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Immune Therapeutics (PK) Charts.
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Immune Therapeutics (PK) Charts.